Differential expression of plasma miR-146a in sepsis patients compared with non-sepsis-SIRS patients

Experimental and Therapeutic Medicine

Volumn 5, Issue 4, 2013, Pages 1101-1104

  Wang, Lina ^a,b   Wang, Hua Cheng ^c   Chen, Cha ^a   Zeng, Jianming ^a   Wang, Qian ^b   Zheng, Lei ^b   Yu, Huan Du ^d  

^a GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c Guangzhou Brain Hospital   (China)

^d Kingmed Diagnostics ^*  (China)

Author keywords

Diagnosis; miR 146a; Sepsis

Indexed keywords

CITRATE SODIUM; EDETIC ACID; MICRORNA 146A; SMALL NUCLEAR RIBONUCLEOPROTEIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84874643328     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.937     Document Type: Article

References (26)

1. Simon L, Gauvin F, Amre DK, Saint-Louis P and Lacroix J: Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39: 206-217, 2004.
2. Tang BM, Eslick GD, Craig JC and McLean AS: Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 7: 210-217, 2007.
3. Young L: Gram-negative sepsis. In: Principles and Practice of Infectious Diseases. Mandell GL, Douglas RG, Bennett JE (eds). Churchill Livingstone, New York, pp 611-636, 1990.
4. Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006, 2008.
5. Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
6. McDonald JS, Milosevic D, Reddi HV, Grebe SK and Algeciras-Schimnich A: Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 57: 833-840, 2011.
7. Ho AS, Huang X, Cao H, et al: Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 3: 109-113, 2010.
8. Taganov KD, Boldin MP, Chang KJ and Baltimore D: NF-kappaB dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103: 12481-12486, 2006.
9. Hou J, Wang P, Lin L, et al: MicroRNA-146a feedback inhibits RIGI-dependent type I IFN production in macrophages by targeting TRAF6, IRAK1 and IRAK2. J Immunol 183: 2150-2158, 2009.
10. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH and Chan EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 10: R101, 2008.
11. Wang JF, Yu ML, Yu G, Bian JJ, Deng XM, Wan XJ and Zhu KM: Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun 394: 184-188, 2010.
12. Bone RC, Balk RA, Cerra FC, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101: 1644-1655, 1992.
13. Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31: 1250-1256, 2003.
14. No authors listed: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864-74, 1992.
15. Dellinger RP, Levy MM, Carlet JM, et al: Surviving sepsis sampaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36: 296-327, 2008.
16. Shapiro NI, Wolfe RE, Moore RB, Smith E, Burdick E and Bates DW: Mortality in Emergency Department Sepsis (MEDS) score: a prospectively derived and validated clinical prediction rule. Critical Care Medicine 31: 670-675, 2003.
17. Takeuchi O, Hoshino K, Kawai T, et al: Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Grampositive bacterial cell wall components. Immunity 11: 443-451, 1999.
18. Vasilescu C, Rossi S, Shimizu M, et al: MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS One, 4, e7405, 2009.
19. Nahid MA, Pauley KM, Satoh M, et al: miR-146a is critical for endotoxin-induced tolerance, implication in innate immunity. J Biol Chem: 284, 34590-34599, 2009.
20. Formisano-Treziny C, de San Feliciano M and Gabert J: Development of plasmid calibrators for absolute quantification of miRNAs by using real-time qPCR. J Mol Diagn 14: 314-321, 2012.
21. Hromadnikova I, Kotlabova K, Doucha J, Dlouha K and Krofta L: Absolute and relative quantification of placenta-specific micrornas in maternal circulation with placental insufficiency related complications. J Mol Diagn 14: 160-167, 2012.
22. Pu XX, Huang GL, Guo HQ, et al: Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 25: 1674-1680, 2010.
23. Tomasetti M, Staffolani S, Nocchi L, et al: Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem 45: 575-581, 2012.
24. Zhang Y, Jia Y, Zheng R, et al: Plasma microRNA-122 as a biomarker fro viral-, alcohol and chemical-related hepatic diseases. Clin Chem 56: 1830-1838, 2010.
25. Starkey Lewis PJ, Dear J, Platt V, et al: Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54: 1767-1776, 2011.
26. Gui J, Tian Y, Wen X, et al: Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond) 120: 183-193, 2011.